Company intelligence / Profile preview

Dewact Labs

Ownership: Private
Development stage: Commercial

Overview

Dewact Labs has developed a rapid point-of-care diagnostic assay ("dewact/flow/") that differentiates between viral and bacterial infections in patients within minutes. The test delivers results in under 10 minutes with 95% accuracy, supporting clinical decision-making to reduce unnecessary antibiotic use and combat antimicrobial resistance[1].

Therapeutic areas: Infectious Diseases
Modalities: DeviceDiagnostic assay (Point-of-care test)
Industry: Protein Biomarker Diagnostics

Drug pipeline

1 asset

dewact/flow

Commercial

Indications: Bacterial infections, Viral infections

Beyond the preview

Go deeper on Dewact Labs.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dewact Labs.

Explore the full profile